[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Petersen VC, Baxter KJ, Love SB, Shepherd NA: Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut; 2002 Jul;51(1):65-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer.
  • BACKGROUND AND AIMS: There is a need for objective easily determined pathological prognostic parameters in Dukes' B colon carcinoma to allow selection of such patients for further treatment as the role of adjuvant chemotherapy for these patients remains unclear.
  • This study was initiated to assess the influence of pathological factors on prognosis in an unselected prospective series of Dukes' B colonic cancer.
  • METHODS: The Gloucester Colorectal Cancer study, established in 1988, recruited more than 1000 cases.
  • Meticulous pathological assessment of the 268 Dukes' B colonic cancer resections in this series included evaluation of all pathological factors that could influence staging and prognosis.
  • CONCLUSIONS: The cumulative prognostic index allows apportionment of patients with Dukes' B colon cancer into defined prognostic groups, which in turn could allow more objective selection of patients for adjuvant therapy, especially as part of clinical trials.
  • [MeSH-major] Colonic Neoplasms / pathology. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]
  • [Cites] Lancet. 1994 Sep 10;344(8924):707-11 [7915774.001]
  • [Cites] Cancer. 1995 Aug 15;76(4):564-71 [8625148.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):35-41 [9102259.001]
  • [Cites] Ann Oncol. 1997 Jan;8(1):65-70 [9093709.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1096-102 [9097991.001]
  • [Cites] J Clin Pathol. 1997 Apr;50(4):266-7 [9215136.001]
  • [Cites] Support Care Cancer. 1997 Jul;5(4):318-21 [9257429.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1349-54 [9579845.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2135-44 [9610692.001]
  • [Cites] J Clin Pathol. 1998 Jun;51(6):481-2 [9771453.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Br J Cancer. 1958 Sep;12(3):309-20 [13596482.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):849-55 [7490320.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):449-56 [10749603.001]
  • [Cites] Br J Surg. 1980 Jun;67(6):439-42 [7388345.001]
  • [Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • [Cites] Lancet. 1987 Jun 6;1(8545):1303-6 [2884421.001]
  • [Cites] Histopathology. 1987 Mar;11(3):259-72 [2828216.001]
  • [Cites] J Clin Pathol. 1989 Feb;42(2):162-6 [2921357.001]
  • [Cites] Histopathology. 1989 Jun;14(6):613-20 [2759558.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Lancet. 1990 May 5;335(8697):1055-9 [1691810.001]
  • [Cites] J Surg Oncol Suppl. 1991;2:36-41 [1909867.001]
  • [Cites] Stat Med. 1992 Dec;11(16):2093-109 [1293671.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [CommentIn] Gut. 2002 Jul;51(1):6-7 [12077080.001]
  • (PMID = 12077094.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1773289
  •  go-up   go-down


2. Machado NO, Chopra PJ, Al Hamdani A: Pancreatic metastasis from colon carcinoma nine years after a hemicolectomy managed by distal pancreatectomy. A review of the literature regarding the role and outcome of pancreatic resection for colorectal metastasis. JOP; 2010;11(4):377-81
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis from colon carcinoma nine years after a hemicolectomy managed by distal pancreatectomy. A review of the literature regarding the role and outcome of pancreatic resection for colorectal metastasis.
  • A case of colonic metastasis to the pancreas is reported and the literature is reviewed to assess the role and outcome of pancreatic resection for metastatic tumors from colorectal malignancy.
  • CASE REPORT: A 58-year-old female underwent an emergency left hemicolectomy for an obstructing descending colon growth.
  • The lesion was reported to be adenocarcinoma, Dukes C, with involvement of the serosa and 3 lymph nodes.
  • A postoperative staging CT scan showed no other metastases and she received 6 cycles of FOLFOX chemotherapy (folinic acid, 5-flurouracil and oxaliplatin).
  • She underwent a distal pancreatectomy, and histopathology of the resected specimen confirmed a metastatic tumor from colon cancer.
  • She then received 5 cycles of adjuvant chemotherapy.
  • The time-interval between the diagnosis of colorectal cancer and the detection of pancreatic metastasis varies widely but is approximately 24 months.
  • The median survival time for post-pancreatic resection is 16 months.
  • [MeSH-major] Carcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Female. Humans. Prognosis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JOP. 2010;11(6):644-5; author reply 650 [21068505.001]
  • (PMID = 20601814.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


3. Garcia V, García JM, Peña C, Silva J, Domínguez G, Hurtado A, Alonso I, Rodriguez R, Provencio M, Bonilla F: Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin Cancer Res; 2006 Apr 1;12(7 Pt 1):2095-100
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.
  • PURPOSE: Thymidylate synthase (TS), a critical target in fluorouracil-based chemotherapy, is a prognostic marker in colon carcinomas and a predictor of response to treatment.
  • Tumor RNA has been detected in plasma from cancer patients and is associated with poor prognosis.
  • This is the first study to examine extracellular TS mRNA in plasma from patients with colon carcinoma, and its possible relation with TS promoter enhancer region (TSER) polymorphism.
  • Patients with TS mRNA in plasma had higher levels of TS in tumor tissue than patients without.
  • CONCLUSIONS: Our results suggest that TS mRNA in plasma originated from tumors, it may indicate poor prognosis and might help to classify tumors in Dukes' stages B and C.
  • [MeSH-major] Colonic Neoplasms / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. RNA, Messenger / genetics. Thymidylate Synthase / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609021.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


Advertisement
4. Mross K, Semsek D: [Chemotherapy of colonic carcinoma in the year 2001]. Praxis (Bern 1994); 2001 Mar 22;90(12):497-510
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy of colonic carcinoma in the year 2001].
  • [Transliterated title] Die Chemotherapie des Kolonkarzinoms im Jahr 2001.
  • The systemic anticancer drug therapy is indicated in the adjuvant as well as in the palliative setting.
  • There is an indication for an adjuvant therapy in case of Dukes B (stadium II) as well as in Dukes C (stadium III) colon cancer.
  • An indication in the palliative setting remains for the Dukes D (stadium IV) colon cancer patients.
  • Locoregional chemotherapeutical approaches represent no standard procedure and cannot be recommended outside clinical trials because the real value of this therapy is unknown due to a lack of large randomized trials.
  • The mainstay of treatment of colon cancer is 5-Fluoruracil (5-FU), which should be combined with folinic acid in case of bolus (2-4 min. injection) therapy.
  • In the adjuvant situation the Mayo scheme administered over a period of half a year remains the standard of choice because this procedure is validated by large randomized trials and replaces the combination 5-FU + levamisol given over a period of one year in former times.
  • In the palliative situation 5-FU based therapy remains the goldstandard although more options than 5-FU plus folinic acid are now available.
  • Oxaliplatin and irinotecan are approved for the treatment of metastatic colon cancer in first line in combination with 5-FU.
  • Capecitabine and Ralitrexed are drugs, which are approved outside of Germany and can be used as well if indicated.
  • The median survival of patients with metastatic colon cancer is between 12 and 18 month.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colonic Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Neoplasm Staging. Palliative Care. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11324309.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; U3P01618RT / Fluorouracil
  • [Number-of-references] 61
  •  go-up   go-down


5. Chung YC, Chang KJ, Yang CC, Lai MT, Hsu CP, Hsueh SF, Peng CC, Fu HH, Chang YF, Yang SD: Association of proline-directed protein kinase FA with tumorigenesis, invasion, and poor prognosis of human colon carcinoma. Cancer; 2002 Nov 1;95(9):1840-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of proline-directed protein kinase FA with tumorigenesis, invasion, and poor prognosis of human colon carcinoma.
  • BACKGROUND: Initial studies revealed that the multisubstrate proline-directed protein kinase F(A) (PDPK F(A)) is overexpressed in various types of human carcinomas relative to normal controls.
  • Suppression of overexpressed PDPK F(A) inhibits the growth of cancer cells, suggesting a role of this PDPK in human malignancy.
  • In this study, we combine immunohistologic, molecular, cellular, animal, and clinicopathologic studies to demonstrate an essential and critical role of PDPK F(A) in progression and poor prognosis of human colon carcinoma.
  • METHODS: The stable antisense clones of human colon carcinoma cells with specific suppression of PDPK F(A) were established for tumorigenesis and invasion studies.
  • In immunohistologic and clinicopathologic studies, the expression and localization of PDPK F(A) were analyzed by immunohistochemical staining of the specimens obtained from human colon carcinoma patients with Dukes Stage B/C.
  • RESULTS: Initial molecular and cellular studies revealed that the antisense clone of colon carcinoma cells (COLO-205) with specific suppression of PDPK F(A) dramatically lost capabilities of adhesion, chemotaxis, and invasion when compared with the parental or control-transfected colon carcinoma cells.
  • This is the first indication of an association of overexpressed PDPK F(A) with colon carcinoma progression.
  • In agreement with this notion, the in vivo study also revealed that the mice injected with the antisense clone with low-level PDPK F(A) only developed very small tumors (< 0.5 cm(3)) even after a 6-week observation.
  • This is in contrast to the parental or control-transfected cells that developed large tumors (> 5 cm(3)) under identical conditions.
  • In contrast, there was no sign of invasion in mice injected with the antisense clone, confirming an essential role of PDPK F(A) in colon carcinoma progression.
  • Clinicopathologic study also revealed that PDPK F(A) is preferentially overexpressed in the invasive area of colon carcinomatous tissues and overexpression of PDPK F(A) is statistically and closely correlated with venous/lymphatic infiltration, lymph node metastasis, and poor prognosis of colon carcinoma patients with Dukes Stage B/C.
  • CONCLUSIONS: The results demonstrate an essential and critical role of overexpressed PDPK F(A) in progression and poor prognosis of colon carcinoma patients.
  • Suppression of overexpressed PDPK F(A) may provide a new powerful adjuvant approach to prevent human colon carcinoma progression and poor prognosis after surgery and chemotherapy.
  • [MeSH-major] Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12404276.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Osuagwu CC, Okafor OC, Ezeome ER, Uche CE, Ememonu C, Kesieme E: Familial adenomatous polyposis with synchronous invasive colonic carcinomas and metastatic jejunal adenocarcinoma in a Nigerian male. Rare Tumors; 2010;2(4):e66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial adenomatous polyposis with synchronous invasive colonic carcinomas and metastatic jejunal adenocarcinoma in a Nigerian male.
  • An intriguing feature of this case is an ulcerated jejunal carcinoma which was metastatic rather than synchronous carcinoma.
  • This patient presented with partial large bowel obstruction and the pathological analysis revealed 4 invasive adenocarcinomas, 3 in the colon and 1 in the jejunum (Dukes stage D).
  • Palliative pancolectomy and jejunal tumour resection with chemotherapy was offered to him.
  • The challenges of managing a hereditary cancer syndrome in a resource poor country are highlighted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Nov 14;14(42):6531-5 [19030207.001]
  • [Cites] East Afr Med J. 1995 Apr;72(4):267-8 [7621765.001]
  • [Cites] West Afr J Med. 2001 Oct-Dec;20(4):251-5 [11885882.001]
  • [Cites] Cent Afr J Med. 1992 Jan;38(1):44-8 [1321689.001]
  • [Cites] Niger J Med. 2005 Apr-Jun;14(2):161-6 [16083239.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):200-4 [16411234.001]
  • [Cites] Cent Afr J Med. 1994 Jan;40(1):8-13 [8082150.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] JOP. 2008;9(1):9-18 [18182737.001]
  • [Cites] Neth J Med. 1989 Jun;34(5-6):317-21 [2549435.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1982-7 [8247073.001]
  • [Cites] Dis Colon Rectum. 1996 May;39(5):536-40 [8620804.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • (PMID = 21234258.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3019601
  • [Keywords] NOTNLM ; adenocarcinoma. / colon / familial adenomatous polyposis / jejunum
  •  go-up   go-down


7. Molnar B, Ladanyi A, Tanko L, Sréter L, Tulassay Z: Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res; 2001 Dec;7(12):4080-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients.
  • PURPOSE: Recently several reverse transcription-PCR techniques have been proven to be useful for the detection of circulating micrometastases.
  • In this study, evaluation and modification of a commercial, cytokeratin-based, immunomagnetic cell separation method was performed for the detection of intact cell clusters in colorectal carcinoma patients.
  • EXPERIMENTAL DESIGN: Thirty-two colon cancer patients (6 were in Dukes stage B, 13 in stage C, and 13 in stage D) and 20 healthy donor samples were evaluated.
  • Immunomagnetic cell separation was performed from the buffy coat of peripheral blood samples (20 ml) using the Carcinoma Cell Enrichment Kit (Miltenyi Biotec, Bergisch Gladbach, Germany), avoiding any filtering steps.
  • Follow-up data indicate that chemotherapy cannot destroy all of the circulating tumor cell clusters.
  • CONCLUSIONS: Using the methods presented, we could detect circulating colon cancer cells and cell clusters in colon carcinoma patients.
  • Present data prove that such structures are present in human colorectal cancer, too.
  • [MeSH-major] Colonic Neoplasms / blood. Colorectal Neoplasms / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2002 Jun;8(6):2015; author reply 2016-7 [12060648.001]
  • (PMID = 11751505.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


8. Ragnhammar P, Hafström L, Nygren P, Glimelius B, SBU-group. Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol; 2001;40(2-3):282-308
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic overview of chemotherapy effects in colorectal cancer.
  • A systematic review of chemotherapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU).
  • This synthesis of the literature on adjuvant and palliative therapy with cytostatics for colorectal cancer is based on 208 scientific articles, including eight meta-analyses and 162 randomised studies.
  • The conclusions reached can be summarized into the following points: The benefit of postoperative adjuvant chemotherapy with fluorouracil and levamisole in patients with colon cancer stage Dukes' C was demonstrated more than ten years ago in two phase III trials.
  • Although this combination has been widely accepted as standard adjuvant treatments for stage Dukes' C colon cancer, there is still debate on whether adjuvant treatment with fluorouracil alone would be equally efficacious.
  • Several phase III trials with postoperative adjuvant chemotherapy with fluorouracil and leucovorin in patients with colon cancer stage Dukes' C have demonstrated a similar statistically significant improvement in disease-free and overall survival in comparison with a control arm.
  • Six months of treatment with fluorouracil and leucovorin is as efficient as twelve months of fluorouracil and levamisole.
  • This treatment is, thus, recommended for routine use.
  • No convincing benefit from adjuvant chemotherapy is proven in colon cancer stage Dukes' B although some randomised trials have shown the same relative survival gain as seen in stage Dukes' C.
  • There is less knowledge on survival benefits from adjuvant chemotherapy for Dukes' stage B and C rectal cancer.
  • In small randomised trials, postoperative radiochemotherapy has, however, improved survival to the same extent as chemotherapy in colon cancer Dukes' stage C.
  • At present, however, the use of portal vein infusion or intraperitoneal therapy outside of a research trial cannot be recommended in the light of the limited effects.
  • In advanced colorectal cancer, chemotherapy may prolong survival, decrease tumour-related symptoms, improve general well-being or maintain it at a high level for a longer time period compared with best supportive care.
  • These effects have been seen using systemic chemotherapy and using regional chemotherapy in patients with metastases limited to the liver.
  • Although the impact on overall survival is modest, i.e. an improvement in median survival of five to six months, treatment is recommended also outside clinical trials.
  • High-dose infusional regimens with modulated fluorouracil may turn out to be superior to conventional bolus regimens, since they result in more tumour regressions, longer times to disease progression and possibly longer survival.
  • Randomised studies of regional therapy, mostly hepatic arterial infusions, of liver metastases in colorectal patients have demonstrated significantly higher response rates than systemic fluorouracil therapy alone without impact on overall survival.
  • Regional therapy in advanced disease cannot be recommended outside of clinical trials.
  • New cytotoxic agents are emerging with antitumour activity similar to fluorouracil-based chemotherapy.
  • Based upon the results of two randomised studies, there is a role for irinotecan as second line therapy for selected patients who have failed first-line therapy with fluorouracil plus leucovorin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Chemotherapy, Adjuvant. Dose-Response Relationship, Drug. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Levamisole / administration & dosage. Neoplasm Staging. Palliative Care. Portal Vein. Prognosis. Randomized Controlled Trials as Topic. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11441937.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 2880D3468G / Levamisole; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 208
  •  go-up   go-down


9. Sakamoto J, Kodaira S, Hamada C, Ito K, Maehara Y, Takagi H, Sugimachi K, Nakazato H, Ohashi Y, Meta-Analysis Group of the Japanese Society of Strategies for Cancer Research and Therapy: An individual patient data meta-analysis of long supported adjuvant chemotherapy with oral carmofur in patients with curatively resected colorectal cancer. Oncol Rep; 2001 May-Jun;8(3):697-703
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An individual patient data meta-analysis of long supported adjuvant chemotherapy with oral carmofur in patients with curatively resected colorectal cancer.
  • To reappraise the benefits of the long supported chemotherapy with carmofur, a meta-analysis based on individual patient data from the three clinical trials was performed by pooling 614 patients from three trials, there is a statistically significant survival benefit (2p=0.032) and disease-free survival (DFS) benefit (2p=0.021) for carmofur; and a highly significant advantage for carmofur in DFS (2p=0.0004) and in survival (2p=0.004) in Dukes' C patients.
  • This IPD meta-analysis strongly suggested an effect of oral carmofur in a long supported chemotherapy for curatively resected colorectal carcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Randomized Controlled Trials as Topic. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11295105.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; HA82M3RAB2 / 1-hexylcarbamoyl-5-fluorouracil; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Belhadj N, Gargouri D, Kharrat J, Ben Hriz F, Kochlef A, Kilani A, Romani M, Ghorbel A, Cherif R, Khlifi S, Ben Maamer A, Letaief A: [A gastroenterology unit experience with adjuvant chemotherapy for non-metastatic colon cancer: results from 24 cases]. Tunis Med; 2003 Jun;81(6):395-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A gastroenterology unit experience with adjuvant chemotherapy for non-metastatic colon cancer: results from 24 cases].
  • [Transliterated title] Chimiotherapie adjuvante des cancers coliques non metastatiques. Expérience d'un service de gastro-entérologie. A propos de 24 cas.
  • A prospective study was carried from January 1996 to December 2000 including patients that received adjuvant chemotherapy type FUFOL for colon carcinoma after curative surgery.
  • Chemotherapy was recommended for all stage Dukes B2 end C.
  • Adjuvant chemotherapy was administered to 24 patients (13 men and 11 women, mean age 56.7 +/- 11.5 years) with surgically resected stage B 2 in 7 cases (29%), C in 17 cases (71%).
  • Treatment was completed in 15 patients (62%).
  • With a median follow-up of 31.6 months, 11 patients had no recurrence, one patient had locoregional recurrence and 2 patients developed liver metastasis.
  • Adjuvant FUFOL chemotherapy is actually the recommended adjuvant post-surgical treatment for colon cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma / drug therapy. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Leucovorin / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Hospital Units. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534945.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Labianca R, Fossati R, Zaniboni A, Torri V, Marsoni S, Nitti D, Boffi L, Scatizzi M, Tardio B, Mastrodonato N, Banducci S, Consani G, Pancera G, ACOI/GIVIO/GISCAD Investigators: Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. J Natl Cancer Inst; 2004 May 19;96(10):750-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.
  • BACKGROUND: 5-fluorouracil-based adjuvant chemotherapy after surgical resection of colon cancer is standard treatment.
  • In a randomized clinical trial of patients with colon cancer, we compared the benefits of chemotherapy delivered by these routes individually or in combination.
  • METHODS: From April 2, 1992, through April 30, 1998, 1084 eligible patients with Dukes' stage B or C colon carcinoma were randomly assigned: 369 patients to the IP regimen (continuous portal vein infusion of 5-fluorouracil at 500 mg/m2 of body surface daily and heparin at 5000 IU daily for 7 consecutive days, beginning on the day of surgery), 358 patients to the SY regimen (six 28-day courses of systemic leucovorin at 100 mg/m2 daily on days 1 through 5 followed by systemic bolus 5-fluorouracil at 370 mg/m2 daily on days 1 through 5, with treatment initiated 15-35 days after surgery), and 357 patients to the IP+SY regimen (the IP regimen followed by the SY regimen, with the same scheduling).
  • RESULTS: At a median follow-up time of 99 months, 389 events (recurrences, second malignancies, or deaths) had occurred, and 361 patients died.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / drug therapy. Portal Vein
  • [MeSH-minor] Administration, Oral. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Italy. Leucovorin / administration & dosage. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Research Design. Risk Factors. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2004 May 19;96(10):727-9 [15150295.001]
  • (PMID = 15150303.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, Spry N, Iacopetta B: p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology; 2000;58(1):52-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.
  • Two common genetic alterations in colon carcinoma, p53 mutation and microsatellite instability (MSI), were investigated to determine their prognostic importance for cancer-specific survival and response to adjuvant chemotherapy in patients with Dukes' C colon cancer.
  • The cellular response mechanisms to DNA-damaging agents in tumours with mutant p53 or MSI may as a consequence differ, and this might translate into different outcomes following adjuvant chemotherapy.
  • A consecutive series of 388 Dukes' C colon carcinomas with 5-year median follow-up was analysed for p53 mutation and for MSI (in proximal/transverse carcinomas only) using polymerase chain reaction single-strand conformation polymorphism.
  • One hundred and thirty-three patients (34%) received adjuvant chemotherapy (5-fluorouracil/levamisole) with curative intent.
  • The presence of MSI in the proximal/transverse colon carcinoma group was associated with significantly better 5-year survival: 58 versus 32% (p = 0.015, log rank test).
  • This was largely due to better survival observed in the MSI subgroup that received adjuvant chemotherapy (p = 0.017, log rank test).
  • Further work in prospective, randomised clinical trials investigating the effects of adjuvant therapy should consider incorporating MSI status in order to determine whether this is an independent predictive factor for survival and/or response to adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / genetics. Colonic Neoplasms / drug therapy. Colonic Neoplasms / genetics. Genes, p53 / genetics. Microsatellite Repeats. Mutation
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Levamisole / administration & dosage. Male. Neoplasm Staging. Polymerase Chain Reaction / methods. Polymorphism, Single-Stranded Conformational. Predictive Value of Tests. Prognosis. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10644941.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Labianca RF, Beretta GD, Pessi MA: Disease management considerations: disease management considerations. Drugs; 2001;61(12):1751-64
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal cancer is still a majorhealth and social problem.
  • However, many important advances in treatment have been made in the last 4 to 5 years, and more optimism is now justified both among clinicians and patients.
  • In surgically resectable disease, adjuvant chemotherapy has been clearly demonstrated as able to increase overall survival in patients with colon cancer Dukes' stage C, whereas the role of medical treatment in patients with Dukes' stage B colon cancer is still controversial.
  • For rectal cancer, the best adjuvant treatment seems to be represented by radiotherapy (better if administered preoperatively) combined with chemotherapy (usually based on modulated or continuously infused 5-FU).
  • In advanced disease, many new drugs have recently emerged: the most active regimens are those combining an optimal modality of 5-FU administration (i.e. continuous infusion) and one of the most active innovative compounds (irinotecan or oxaliplatin).
  • The role of the oral drugs (e.g. tegafur/uracil, capecitabine) is still under investigation as is the combination of agents excluding 5-FU.
  • It is now recognised that first-line treatment must be offered to all suitable pa- tients, even though asymptomatic, and that a second-line therapy (chiefly with irinotecan) is of value in many patients with cancer that progresses during treatment with 5-FU.
  • From a strategic point of view, the best sequence of drugs/regimens has not yet been defined, while the duration and timing of chemotherapy is still a matter for clinical research.
  • Finally, there is an increasing interest in the role of biological prognostic factors as an aid to a patient-tailored therapy, both in the adjuvant setting and in advanced disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Humans. Liver / physiopathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] Ann Intern Med. 1987 Oct;107(4):459-65 [2957943.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14 ):980-7 [9091798.001]
  • [Cites] Radiother Oncol. 1996 Aug;40(2):127-35 [8884966.001]
  • [Cites] Eur J Cancer. 1999 Sep;35(9):1338-42 [10658524.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):35-41 [9102259.001]
  • [Cites] Cancer Causes Control. 2000 Jul;11(6):555-63 [10880038.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):581-5 [8879371.001]
  • [Cites] Lancet. 1995 Feb 11;345(8946):349-53 [7845115.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2296-300 [7964943.001]
  • [Cites] Lancet. 1997 Sep 6;350(9079):681-6 [9291901.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] J Clin Oncol. 1996 Mar;14 (3):709-15 [8622015.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):808-15 [9053508.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2528-33 [9667274.001]
  • [Cites] Ann Oncol. 1994 Mar;5(3):233-7 [8186170.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] Clin Cancer Res. 1995 Sep;1(9):955-60 [9816066.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):267-74 [7542021.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • [Cites] Cancer. 1999 Oct 15;86(8):1421-30 [10526268.001]
  • [Cites] Postgrad Med J. 1996 Aug;72(850):464-9 [8796208.001]
  • [Cites] Ann Surg. 1997 Feb;225(2):193-201 [9065296.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1413-8 [9807987.001]
  • [Cites] Ann Oncol. 1996 Nov;7(9):961-5 [9006748.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):893-900 [1735081.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):243-54 [10637236.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):549-57 [1548520.001]
  • [Cites] J Clin Oncol. 1989 Apr;7(4):425-32 [2926468.001]
  • [Cites] Lancet. 1994 May 14;343(8907):1177-83 [7909866.001]
  • [Cites] Oncology (Williston Park). 1997 Mar;11(3):295-300, 305; discussion 306 passim [9109124.001]
  • [Cites] Ann Oncol. 2000 Nov;11(11):1413-20 [11142481.001]
  • [Cites] Lancet. 2000 Jul 29;356(9227):353-4 [10972363.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3560-8 [10550155.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):904-11 [1588370.001]
  • [Cites] Lancet. 2000 Jul 29;356(9227):373-8 [10972369.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):252-8 [8614003.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):625-30 [2066758.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1608-17 [7932825.001]
  • [Cites] Acta Oncol. 1992;31(6):645-51 [1281650.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):663-9 [10442188.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):214-9 [9135491.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):597-604 [11290435.001]
  • (PMID = 11693464.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; U3P01618RT / Fluorouracil
  • [Number-of-references] 70
  •  go-up   go-down


14. Di Costanzo F, Sobrero A, Gasperoni S, Dogliotti L, Frassineti L, Falcone A, Lionetto R, Bruzzi P, Luppi G, Gallo L, Conte P, Comandone A, Turci D, Marzola M, Folco U, Pfanner E, Mestriner M, Boni C, Galli C, Tonato M, Rosso R, Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC): Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Ann Oncol; 2003 Sep;14(9):1365-72
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).
  • BACKGROUND: To determine whether the addition of leucovorin to the combination 5-fluorouracil plus levamisole prolongs disease-free survival and overall survival in patients with radically resected colon cancer (Dukes' B(2-3) and C).
  • CONCLUSIONS: In this trial the schedules used showed no statistically significant differences in terms of disease-free survival or overall survival in the treatment of colorectal cancer.

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2003 Sep;14(9):1338-9 [12954571.001]
  • (PMID = 12954574.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 2880D3468G / Levamisole; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Seo P: Cases from the medical grand rounds of the Osler Medical Service at Johns Hopkins University. Am J Med; 2002 Jun 15;112(9):730-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two weeks before admission, he developed gradually worsening shortness of breath.
  • One week before admission, he developed a cough that initially was nonproductive but later was associated with hemoptysis.His past medical history was remarkable for a history of colon cancer (Dukes' stage III), for which he underwent a hemicolectomy and treatment with adjuvant chemotherapy in 1993.
  • He also had a history of hypertension, type 2 diabetes, and gout.
  • Serologies were remarkable for an antinuclear antibody titer of 1:320 and a P-antineutrophil cytoplasmic antibody (P-ANCA) titer of greater than 1:320.

  • MedlinePlus Health Information. consumer health - Vasculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12079715.001).
  • [ISSN] 0002-9343
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol; 2003 Jan 15;21(2):241-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
  • PURPOSE: To define the value of thymidylate synthase (TS), Ki-67, and p53 as prognostic markers in patients with stage II and III colon carcinoma.
  • PATIENTS AND METHODS: We retrospectively analyzed the prognostic value of TS, Ki-67, and p53 in 706 patients with Dukes' B (291 patients) or Dukes' C (415 patients) colon carcinoma who were treated with either surgery alone (275 patients) or surgery plus fluorouracil (FU)-leucovorin chemotherapy (431 patients) in National Surgical Adjuvant Breast and Bowel Project (NSABP) protocols C01-C04.
  • An interaction with treatment was not identified for any of the markers.
  • CONCLUSION: This retrospective investigation demonstrated that TS, Ki-67, and p53 staining each had significant prognostic value for patients with Dukes' B and C colon carcinoma.
  • However, none of the markers could be used to clearly discern groups of individuals who would be predicted to derive greater or lesser benefit from the use of adjuvant chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / chemistry. Ki-67 Antigen / analysis. Thymidylate Synthase / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colectomy. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Immunoenzyme Techniques. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12525515.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA12027; United States / NCI NIH HHS / CA / U10CA37377; United States / NCI NIH HHS / CA / U10CA69651; United States / NCI NIH HHS / CA / U10CA69974
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.1.1.45 / Thymidylate Synthase; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. André T, Tuvignon N, Taieb J, Vaillant JC, Hannoun L, de Gramont A: [Operable colon cancer: initial strategy]. Rev Prat; 2010 Oct 20;60(8):1089-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operable colon cancer: initial strategy].
  • [Transliterated title] Cancer du côlon opérable: quelle stratégie de prise en charge initiale?
  • Individual screening of patients with personal or family history of colon cancer or polyps, or patients with an inflammatory condition of the digestive tract, combined with the generalization of mass screening using Hemoccult, have modified the way colon cancer is diagnosed.
  • The optimization of colon surgery, together with adjuvant chemotherapy, has improved the 5- and 10-year survival.
  • The five-year survival rate is now comprised between 90 percent in patients with stage-I colon cancer, and 65-70 percent in patients with stage-III colon cancer.
  • More than half patients suffer from stage-II (T3-T4 N0) or stage-III (TxN+) cancer, and 30 to 40 percent of these patients experience cancer recurrence without adjuvant therapy within 5 years following surgery.
  • In patients with surgically-resected colon cancer, these recurrences are mostly metastatic (liver, lungs, peritoneum), local recurrences remain uncommon.
  • An adjuvant therapy combining oxaliplatin and fluoropyrimidine is clearly indicated in patients with stage-III colon tumor (20-percent improvement of survival without recurrence), and can be considered in stage-III patients.
  • This treatment is not indicated in patients with stage-I tumor.
  • [MeSH-major] Colonic Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Decision Making. Humans. Neoplasm Recurrence, Local / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21197740.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


18. Kim R, Yamaguchi Y, Toge T: Adjuvant therapy for colorectal carcinoma. Anticancer Res; 2002 Jul-Aug;22(4):2413-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy for colorectal carcinoma.
  • Adjuvant therapy for colorectal carcinoma has been developed over the last two decades.
  • We have reviewed the history of adjuvant chemotherapy for colorectal carcinoma in the United States, Europe and Japan with regard to the rationale of the chemotherapy regimen and the survival benefit for the establishment of a standard regimen.
  • Treatment with 5-fluorouracil (5-FU) and leucovorin (LV) for postoperative adjuvant chemotherapy had an overall survival benefit, compared with surgery alone, in randomized controlled trials in the United States and Europe for Dukes' C colon carcinoma.
  • In contrast, the survival benefit of adjuvant chemotherapy for Dukes' B colon carcinoma and for rectal carcinoma has not yet been established.
  • In Japan, randomized controlled trials have examined combination treatment with mitomycin (MMC) and oral fluoropyrimidines for colorectal carcinoma compared with surgery alone.
  • A meta-analysis indicated that combination treatment with MMC and oral fluoropyrimidines had a survival benefit for colorectal carcinoma.
  • The survival benefit of combination treatment with irinotecan (CPT-11) + 5-FU + LV or uracil + tegaful (UFT) + LV (Orzel) for adjuvant chemotherapy are currently being compared with 5-FU + LV.
  • The survival benefit of preoperative radiotherapy was superior to postoperative radiotherapy for advanced rectal carcinoma in association with the prevention of local recurrence.
  • Clinical trial data suggest that the current standard regimen of adjuvant chemotherapy is a combination of 5-FU and LV for Dukes' C colon carcinoma and that radiotherapy for local control of rectal carcinoma has a survival benefit.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174936.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 50
  •  go-up   go-down


19. Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS, Yen CC, Lin TC, Jiang JK, Yang SH, Wang HS, Chen PM: Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol; 2000 Jan;30(1):12-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience.
  • BACKGROUND: Preoperative carcinoembryonic antigen (CEA) level is considered as a factor predictive of survival in colorectal cancer patients.
  • This study was carried out in an effort to evaluate the prognostic significance of preoperative CEA levels of patients with colorectal cancer in Taiwan.
  • 5-Fluorouracil-based adjuvant chemotherapy was administered if the patients had Dukes' C disease.
  • Reference to the Dukes' classification was according to the classical criteria described in 1932 for carcinoma of the rectum and adapted for use in colonic tumors.
  • By multivariate Cox analysis, lymph node metastases (p = 0.003), penetration of the bowel wall (p = 0.0001) and preoperative CEA levels (p = 0.0001) were found to be independent prognostic factors in colorectal cancer patients.
  • CONCLUSIONS: The data from our study indicate that in addition to lymph node metastases and penetration of the bowel wall, the preoperative CEA levels are also an independent prognostic factor in non-metastatic colorectal cancer patients after curative surgery.
  • This could serve as an appropriate modification to the initial Dukes' scheme in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / blood. Carcinoembryonic Antigen / blood. Colonic Neoplasms / blood. Rectal Neoplasms / blood
  • [MeSH-minor] Age Factors. Analysis of Variance. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Colon / pathology. Female. Fluorouracil / therapeutic use. Forecasting. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Prognosis. Proportional Hazards Models. Rectum / pathology. Retrospective Studies. Sex Factors. Survival Rate. Taiwan

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Jpn J Clin Oncol. 2000 Nov;30(11):522-3 [11155925.001]
  • (PMID = 10770562.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Carcinoembryonic Antigen; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Scott RH, Mansour S, Pritchard-Jones K, Kumar D, MacSweeney F, Rahman N: Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol; 2007 Feb;4(2):130-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations.
  • Background A 13-year-old girl presented with rectal bleeding and was found to have two colonic carcinomas (stage Dukes' C) and multiple colonic polyps.
  • At the age of 7 years she had widespread hyperpigmented and hypopigmented skin lesions, and had developed medulloblastoma, which was treated with chemotherapy and craniospinal irradiation.
  • At the age of 10 years she had developed acute myelocytic leukemia, M5.
  • She was treated with chemotherapy including sibling bone marrow transplant with busulfan/cyclophosphamide conditioning.
  • A three-generation family history identified no relatives with colonic carcinomas or polyposis.
  • Investigations Immunohistochemical analysis was performed on a sample of colonic adenoma.
  • Management Cascade genetic testing and colonoscopic screening for colorectal carcinoma has been offered to relatives carrying one mutation.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Colonic Neoplasms / genetics. DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Medulloblastoma / genetics


21. Wang WS, Chen PM, Chiou TJ, Liu JH, Fan FS, Lin TC, Jiang JK, Yang SH, Yen CC, Wang HS, Lin JK: Factors predictive of survival in patients with node-positive colorectal cancer in Taiwan. Hepatogastroenterology; 2000 Nov-Dec;47(36):1590-4
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predictive of survival in patients with node-positive colorectal cancer in Taiwan.
  • BACKGROUND/AIMS: Preoperative CEA levels, depth of tumor penetration, and the number of positive lymph nodes were reported as independent factors prognostic of survival in colorectal cancer patients.
  • This study was carried out in an effort to evaluate the prognostic significance of these three factors in patients with Dukes' C colorectal cancer in Taiwan.
  • METHODOLOGY: Between 1992 and 1994, a total of 112 patients with node-positive colorectal cancer were evaluated retrospectively at the Veteran General Hospital-Taipei.
  • All patients underwent potentially curative surgery and received 5-fluorouracil based adjuvant chemotherapy.
  • Reference to the Dukes' classification was according to the classical criteria described in 1932 for carcinoma of the rectum and adapted for use in colonic tumors.
  • Using multivariate Cox analysis the number of positive lymph nodes, penetration of the bowel wall, and preoperative CEA levels were still found as independent prognostic factors in node-positive colorectal cancer patients.
  • CONCLUSIONS: Data obtained from our study indicates that preoperative CEA levels, depth of tumor penetration, and the number of positive lymph nodes were independent prognostic factors in Dukes' C colorectal cancer patients.
  • They could serve as appropriate modifications of the initial Dukes scheme in node-positive diseases.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11149009.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


22. Melissas J, Schoretsanitis G, Daskalakis M, Tsiftsis DD: Sigmoidoduodenal fistula as a rare complication of colonic carcinoma: report of a case. Surg Today; 2003;33(8):623-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sigmoidoduodenal fistula as a rare complication of colonic carcinoma: report of a case.
  • A sigmoidoduodenal fistula was found by barium enema, and a diagnosis of ulcerative colonic adenocarcinoma was made from the colonoscopy findings.
  • Histological examination confirmed a Dukes' B (Stage II - T(4)N(0)M(0)) colonic adenocarcinoma, and the excision margins of the resected duodenal specimen were clear.
  • We gave adjuvant chemotherapy with 5-fluorouracil and leucovorin.
  • [MeSH-major] Adenocarcinoma / complications. Colonic Neoplasms / complications. Duodenal Diseases / etiology. Intestinal Fistula / etiology. Sigmoid Diseases / etiology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male

  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12884103.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 12
  •  go-up   go-down


23. Sakamoto J, Hamashima H, Suzuki H, Ito K, Mai M, Saji S, Fukushima M, Matsushita Y, Nakazato H: Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial. Oncol Rep; 2003 Sep-Oct;10(5):1081-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial.
  • The expression levels of thymidylate synthase (TS) affect the sensitivity of tumor cells to fluorinated pyrimidine cytotoxic agents and determine the response of patients with colorectal cancer to fluorinated-pyrimidine-based chemotherapy.
  • The correlation between the expression of TS and the prognosis of patients with colorectal cancer was examined in a prospective study.
  • Evaluation of biomarkers including TS expression was performed using tumor specimens from 229 colorectal cancer patients.
  • In a subset analysis of Dukes' stage C patients, the survival and DFS rates were 44.0% and 40.0% in the high TS expression group, and 73.5% and 67.4% in the low TS expression group, respectively.
  • Significantly poorer prognosis of curatively resected colon cancer in patients with high TS expression levels in tumor tissue was confirmed by a double-blind prospective study conducted on samples obtained from patients enrolled in an adjuvant immunochemotherapy randomized clinical trial.
  • [MeSH-major] Colonic Neoplasms / metabolism. Immunotherapy / methods. Thymidylate Synthase / biosynthesis
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / chemistry. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Chemotherapy, Adjuvant. Disease-Free Survival. Double-Blind Method. Epitopes. Female. Follow-Up Studies. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Prospective Studies. Pyrimidines / therapeutic use. Random Allocation. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12883662.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Pyrimidines; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


24. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O'Connell MJ, Levitt R, Kugler JW, Tria Tirona M, Goldberg RM: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol; 2002 Apr 1;20(7):1735-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer.
  • PURPOSE: To evaluate the value of thymidylate synthase (TS), Ki-67, and p53 as prognostic markers in patients with Dukes' B2 and C colon carcinoma.
  • METHODS: We conducted a retrospective analysis to evaluate the prognostic value of TS, Ki-67, and p53 in 465 patients with Dukes' B2 (220 patients) or Dukes' C (245 patients) colon carcinoma.
  • Patients represent a nonrandom subset obtained from five randomized phase III trials and were treated with either surgery alone (151 patients) or surgery plus fluorouracil-based chemotherapy (314 patients).
  • Patients whose tumors stained positively for p53 seemed to benefit substantially from the use of adjuvant chemotherapy compared with those who were not treated (P =.05).
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / chemistry. Ki-67 Antigen / analysis. Thymidylate Synthase / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colectomy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11919229.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA15083; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / CA35101; United States / NCI NIH HHS / CA / CA35103; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA35195; United States / NCI NIH HHS / CA / CA35269; United States / NCI NIH HHS / CA / CA35272; United States / NCI NIH HHS / CA / CA35415; United States / NCI NIH HHS / CA / CA37404; United States / NCI NIH HHS / CA / CA37417; United States / NCI NIH HHS / CA / CA52352; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA63849
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. George ML, Tutton MG, Abulafi AM, Eccles SA, Swift RI: Plasma basic fibroblast growth factor levels in colorectal cancer: a clinically useful assay? Clin Exp Metastasis; 2002;19(8):735-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma basic fibroblast growth factor levels in colorectal cancer: a clinically useful assay?
  • Angiogenic cytokines in the plasma and serum of cancer patients may serve as 'surrogate' markers of tumour neoangiogenesis.
  • Serum VEGF correlates with disease stage in colorectal cancer (CRC), but the role of bFGF in CRC is uncertain.
  • This study aimed to assess plasma bFGF levels in CRC patients before treatment, during chemoradiotherapy and at one-year follow-up.
  • There were no detectable differences between plasma bFGF levels in polyp, Dukes' A or B patients (4.55, 5.77, 4.25 pg/ml, respectively), but there was a significant increase in metastatic CRC patients [Dukes' C and D (7.42 and 6.6 pg/ml; P = 0.004 and 0.048, respectively)], relative to median control levels of 4.14 pg/ml.
  • At follow-up, there was a significant fall in plasma bFGF levels in disease-free patients (pre-op 6.09 and follow-up 3.45 pg/ml, P = 0.0004), but a non-significant rise in 18 patients with progressive disease (pre-treatment 5.90 and follow-up 9.99 pg/ml, P = 0.33).
  • Pre-treatment plasma bFGF in patients receiving chemo-radiotherapy was similar in those with responsive and non-responsive tumours.
  • There were no detectable changes in plasma bFGF through the adenoma-carcinoma sequence or patient groups with non-metastatic cancers.
  • The significant fall in bFGF in disease-free patients following therapy suggests that bFGF may be useful in clinical practice.
  • [MeSH-minor] Colonic Polyps / blood. Colonic Polyps / drug therapy. Colonic Polyps / radiotherapy. Colonic Polyps / surgery. Combined Modality Therapy. Humans. Reference Values

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12553380.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


26. Soran A, Harlak A, Wilson JW, Nesbitt L, Lembersky BC, Wienad HS, O'Connell MJ: Diverticular disease in patients with colon cancer: subgroup analysis of national surgical adjuvant breast and bowel project protocol C-06. Clin Colorectal Cancer; 2006 Jul;6(2):140-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diverticular disease in patients with colon cancer: subgroup analysis of national surgical adjuvant breast and bowel project protocol C-06.
  • BACKGROUND: Similar epidemiologic characteristics suggest a common etiology for colon cancer (CC) and diverticular disease of the colon (DD).
  • National Surgical Adjuvant Breast and Bowel Project (NASBP) protocol C-06 is a clinical trial comparing oral uracil/tegafur/leucovorin with 5-fluorouracil/leucovorin in patients with resected stage II/III carcinoma of the colon.
  • PATIENTS AND METHODS: The NASBP enrolled 1,608 patients who had undergone potentially curative resection for stage II/III colon cancer from 256 medical sites between February 14, 1997, and March 31, 1999.
  • Colon cancer was located in the rectosigmoid in 46.88% of patients with DD and in 31.92% of patients without DD (P < 0.05).
  • A baseline diagnosis of DD made no significant contribution to DFS or OS without adjustment for confoundin factors (P = 0.2 and P = 0.32, respectively) or adjusted for Dukes classification and age (P = 0.49 and P = 0.68, respectively).
  • There was no negative impact of having DD on DFS and OS in patients treated for stage II/III CC.
  • [MeSH-major] Colonic Neoplasms / complications. Colonic Neoplasms / drug therapy. Diverticulum, Colon / etiology

  • Genetic Alliance. consumer health - Diverticular Disease.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945170.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA-12027; United States / NCI NIH HHS / CA / U10CA-37377; United States / NCI NIH HHS / CA / U10CA-69651; United States / NCI NIH HHS / CA / U10CA-69974
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Yu ZG, Sun JZ, Zhang Q, Jia HY, Wang JX: [Relationship between expression of thymidylate synthase and colorectal carcinoma]. Zhonghua Yi Xue Za Zhi; 2004 Sep 2;84(17):1432-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between expression of thymidylate synthase and colorectal carcinoma].
  • OBJECTIVE: To study the relationship between the expression of thymidylate synthase (TS) gene and the prognosis of colorectal carcinoma and between the TS expression and the effect of 5-fluorouracil (5-Fu) on advanced colorectal carcinoma.
  • METHODS: 134 formalin-fixed and paraffin-embedded specimens of colorectal carcinoma obtained during operation from 134 patients, 65 males and 69 females, aged 34 approximately 76 with an average age of 51 +/- 11, 16 with differentiated carcinoma and 118 with undifferentiated carcinoma, 4 with infiltration into mucous layer, 21 into submucous layer, 100 into muscular layer, and 5 into serous layer, 25 without lymphatic metastasis and 109 with lymphatic metastasis, 4 in stage IB, 15 in stage II, 90 in stage IIIA, and 27 in stage IIIB by Dukes staging, underwent immunohistochemistry (ABC methods) to determine the expression of TS.
  • After operation all patients received chemotherapy with leucovorin and 5-Fu for 4 approximately 6 periods and were followed up for 9 approximately 72 months.
  • The grade of TS expression was significantly correlated with four clinicopathologic variables: histological type, depth of invasion, lymphatic metastasis, and Dukes' stage (all P < 0.001).
  • Multivariate analysis revealed that three variables (histological type, depth of infiltration, and TS grade) independently contributed to the survival rate (all P < 0.05), especially the TS grade (all P < 0.0001).
  • CONCLUSION: The expression of TS is one of the important prognosis indicators of colorectal carcinoma.
  • It is also a relatively reliable indicator of whether 5-Fu should be used in the treatment of patients with colorectal carcinoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / enzymology. Fluorouracil / therapeutic use. Rectal Neoplasms / enzymology. Thymidylate Synthase / biosynthesis
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15500737.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C, X-ACT Study Group: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol; 2003 Dec;14(12):1735-43
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
  • BACKGROUND: Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil-leucovorin (5-FU/LV) as first-line treatment for patients with metastatic colorectal cancer.
  • We report here the results of a large phase III trial investigating adjuvant oral capecitabine compared with 5-FU/LV (Mayo Clinic regimen) in Dukes' C colon cancer.
  • PATIENTS AND METHODS: Patients aged 18-75 years with resected Dukes' C colon carcinoma were randomized to receive 24 weeks of treatment with either oral capecitabine 1250 mg/m(2) twice daily, days 1-14 every 21 days (n = 993), or i.v. bolus 5-FU 425 mg/m(2) with i.v. leucovorin 20 mg/m(2) on days 1-5, repeated every 28 days (n = 974).
  • CONCLUSIONS: Based on its improved safety profile, capecitabine has the potential to replace 5-FU/LV as standard adjuvant treatment for patients with colon cancer.
  • Efficacy results are expected to be available in Keywords: Adjuvant treatment, capecitabine, chemotherapy, colorectal cancer

  • Genetic Alliance. consumer health - Oral cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14630678.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


29. Ishida H, Tatsuta M, Furukawa H, Ohta H, Hashimoto K, Hayashi N, Morimoto O, Ikeda M, Miya A, Masutani S, Kawasaki T, Satomi T, Yoshioka H, Hanai J: Multiple inflammatory pseudotumors mimicking liver metastasis from colon cancer: report of a case. Surg Today; 2000;30(6):530-3
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple inflammatory pseudotumors mimicking liver metastasis from colon cancer: report of a case.
  • A 54-year-old man underwent an operation for colon cancer histologically diagnosed as moderately differentiated adenocarcinoma with clinical staging of Dukes C.
  • He was prescribed carmofur for adjuvant chemotherapy.
  • A follow-up computed tomography scan done 6 months later revealed two new low-density areas in the liver.
  • A diagnosis of metastatic adenocarcinoma from the previous colon cancer was presumed, based on the patient's history and radiological findings, and resection of the affected area of liver was performed.
  • IPT of the liver is a rare disease, for which no methods of diagnosis and treatment have been established, since it is difficult to distinguish IPT from hepatocellular carcinoma or metastatic carcinoma.
  • We describe this case with a review of the 101 cases of IPT documented in the Japanese literature, in the hope that it will contribute to the diagnosis and treatment of this unusual disease entity.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Granuloma, Plasma Cell / diagnosis. Liver Diseases / diagnosis. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1989 Mar-Apr;33(2):259-62 [2929226.001]
  • [Cites] Am J Clin Pathol. 1978 Feb;69(2):176-81 [629225.001]
  • [Cites] J Surg Oncol. 1989 Apr;40(4):283-7 [2927142.001]
  • [Cites] J Clin Pathol. 1997 Apr;50(4):352-3 [9215157.001]
  • [Cites] Am J Gastroenterol. 1998 Sep;93(9):1538-40 [9732940.001]
  • [Cites] Ann Surg. 1953 Aug;138(2):253-8 [13066016.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1583-90 [2155699.001]
  • (PMID = 10883465.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 12
  •  go-up   go-down


30. Gennatas C, Mouratidou D, Androulakis G, Georgoulias V, Tsavaris N, Philippakis M, Michailakis E, Kalofonos C, Mpesmpeas S, Katsos J, Tsitoura M, Retalis G, Mallas E, Voros D, Andreadis C, Hatzistylianos G, Pisiotis C, Kamilarios D, Kakoliris S, Komporozos V, Kannas D, Legakis N, Mpatakis T, Ntamtsios J, Papaevangelou E, Peros G, Photopoulos A, Pouli A, Prigouris S, Samanidis L, Sakellariou V, Smyrniotis V, Polymeneas G, Vasiliou J, Athanasiou A, Papadimitriou J: Adjuvant systemic therapy protocol for Dukes' B2 and C resectable colon carcinoma. Tumori; 2002 Jan-Feb;88(1):32-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant systemic therapy protocol for Dukes' B2 and C resectable colon carcinoma.
  • AIMS AND BACKGROUND: Trials of adjuvant systemic therapy in high risk patients with Dukes' B2 and C colon cancer utilizing 5-fluorouracil-based regimens have been ongoing since the 1960s.
  • STUDY DESIGN: A total of 322 patients with histologically proven adenocarcinoma of the colon, Dukes' stage B2 and C, were entered in the study.
  • They were randomized to A) leucovorin 20 mg/m2 rapid intravenous injection and 5-FU 425 mg/m2 IV days 1-5 every 28 days for six cycles or B) 5-FU 600 mg/m2 24-hour infusion for five days, then 600 mg/m2 IV once a week and IFN 5 MU subcutaneously three times a week for six months.
  • These data do not support the use of IFN in combination with 5-FU as systemic adjuvant therapy for patients with locally advanced colon carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Interferon-alpha / administration & dosage. Leucovorin / administration & dosage. Male. Neoplasm Staging. Recombinant Proteins. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12004847.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 43K1W2T1M6 / interferon alfa-2b; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Salas-Valverde S, Lizano A, Gamboa Y, Vega S, Barrantes M, Santamaría S, Zamora JB: Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases. Pediatr Surg Int; 2009 Dec;25(12):1073-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases.
  • BACKGROUND: Carcinoma of the colon and rectum is rare in the pediatric age group, and usually presents with an advanced stage disease bearing a poor prognosis.
  • Colorectal carcinoma should be considered in children with signs of intestinal obstruction, alteration in bowel habits, gastrointestinal bleeding and chronic abdominal pain.
  • METHODS: Between 1974 and 2007, 11 patients were identified and treated for colorectal carcinoma at the Oncology Unit.
  • The medical records were studied to analyze the age, sex, clinical presentation, diagnostic procedures, extent of disease (Dukes staging), treatment, histological types, and outcome.
  • Predisposing diseases and syndromes were encountered in three children, (1 with Turner's syndrome and two with adenomatous familial polyposis).
  • Surgical procedures were done in 11 patients (incomplete resection with segmental resection in 4 patients, complete resection in the other 4, and biopsy alone in 3 patients).The predominant histological type was mucinous carcinoma.
  • Seven patients received adjuvant chemotherapy, all of whom did not survive.
  • CONCLUSIONS: Colorectal carcinoma in children is very uncommon and could be easily misdiagnosed, resulting in advanced stage disease at diagnosis.
  • Because radical surgery which is the mainstay of treatment is possible only in patients with early stage disease, a high level of awareness and early diagnosis are critical.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Antineoplastic Agents / therapeutic use. Colectomy / methods. Colonic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Biopsy. Chemotherapy, Adjuvant. Child. Colonoscopy. Costa Rica / epidemiology. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Humans. Male. Prognosis. Retrospective Studies. Survival Rate / trends

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):39-41 [15654277.001]
  • [Cites] Cancer. 1958 Jul-Aug;11(4):855-7 [13561255.001]
  • [Cites] Surg Gynecol Obstet. 1962 Apr;114:438-42 [13898554.001]
  • [Cites] J Pediatr Surg. 1976 Dec;11(6):967-71 [1003308.001]
  • [Cites] Clin Genet. 1987 Jan;31(1):35-44 [3568432.001]
  • [Cites] Am Surg. 1998 Sep;64(9):849-53 [9731812.001]
  • [Cites] Pediatrics. 1963 Oct;32:558-71 [14069097.001]
  • [Cites] J Chemother. 2002 Jun;14(3):301-8 [12120887.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1085-9; discussion 1089-90 [1403541.001]
  • [Cites] Eur J Pediatr Surg. 2003 Feb;13(1):66-8 [12664421.001]
  • [Cites] Dis Colon Rectum. 1976 Sep;19(6):529-34 [183939.001]
  • [Cites] Eur J Pediatr Surg. 2001 Oct;11(5):338-41 [11719875.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):952-5 [4016687.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1322-6 [3971300.001]
  • [Cites] J Pediatr Surg. 1999 Oct;34(10):1499-504 [10549756.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):919-21 [1640344.001]
  • [Cites] J Pediatr Surg. 1993 Sep;28(9):1188-93 [8308690.001]
  • [Cites] Arch Surg. 1970 Apr;100(4):527-31 [4190476.001]
  • [Cites] Dis Colon Rectum. 1981 Jan-Feb;24(1):25-8 [7472098.001]
  • [Cites] Surgery. 1983 Mar;93(3):409-14 [6600855.001]
  • [Cites] Am J Surg. 1958 Jul;96(1):47-53 [13545485.001]
  • [Cites] Surg Gynecol Obstet. 1974 Feb;138(2):169-70 [4810853.001]
  • [Cites] Br J Surg. 1984 Apr;71(4):272-7 [6704677.001]
  • [Cites] Cancer. 1976 Apr;37(4):1891-1900 [177180.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1560-2 [14605580.001]
  • [Cites] Cancer. 1977 Nov;40(5 Suppl):2464-72 [200342.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):209-11 [17255833.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5808-14 [18089879.001]
  • [Cites] J Pediatr Surg. 1989 Nov;24(11):1189-91 [2553912.001]
  • [Cites] South Med J. 1976 Jan;69(1):24-7 [1246645.001]
  • (PMID = 19816697.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


32. Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N: Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst; 2004 Aug 4;96(15):1128-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.
  • BACKGROUND: The National Surgical Adjuvant Breast and Bowel Project C-01 trial reported in 1988 that, for patients with adenocarcinoma of the colon, compared with surgery alone, 1) postoperative chemotherapy with 1-(2-chloroethyl)-3-(4-trans-methylcyclohexyl)-1-nitrosourea (i.e., MeCCNU or semustine), vincristine, and 5-fluorouracil was associated with better 5-year disease-free and overall survival and 2) postoperative immunotherapy with bacillus Calmette-Guérin was associated with better 5-year overall, but not disease-free, survival.
  • METHODS: Between November 11, 1977, and February 28, 1983, 1166 patients with resected Dukes' stage B and C adenocarcinoma of the colon were stratified by Dukes' stage, sex, and age (<65 years or > or =65 years) and then randomly assigned to receive no further treatment (surgery alone; 394 patients), adjuvant chemotherapy (379 patients), or adjuvant immunotherapy (393 patients).
  • Those eligible for follow-up included 375 (95.2%) patients in the surgery-alone group, 349 (92.1%) patients in the adjuvant-chemotherapy group, and 372 (94.7%) patients in the adjuvant-immunotherapy group.
  • RESULTS: No difference was observed between patients in the chemotherapy group and those in the surgery-alone group in 10-year disease-free survival (hazard ratio [HR] = 1.14, 95% confidence interval [CI] = 0.94 to 1.39;P =.17) or overall survival (HR = 1.12, 95% CI = 0.91 to 1.38; P=.27).
  • CONCLUSION: The disease-free and overall survival benefit associated with chemotherapy in this patient population is of limited duration, disappearing after 10 years.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / surgery. Immunotherapy / methods. Mycobacterium bovis / immunology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Likelihood Functions. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Proportional Hazards Models. Randomized Controlled Trials as Topic. Semustine / administration & dosage. Survival Analysis. Treatment Outcome. United States. Vincristine / administration & dosage

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Semustine .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2004 Dec 1;96(23):1794; author reply 1794 [15572762.001]
  • [CommentIn] J Natl Cancer Inst. 2004 Aug 4;96(15):1116-7 [15292377.001]
  • (PMID = 15292384.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69651; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 13909-09-6 / Semustine; 5J49Q6B70F / Vincristine; U3P01618RT / Fluorouracil; MOF protocol
  •  go-up   go-down






Advertisement